The use of sugammadex in a patient with myasthenia gravis

Anaesthesia

Volumn 65, Issue 3, 2010, Pages 302-305

  Unterbuchner, Christoph ^a   Fink, H ^b   Blobner, M ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; PROPOFOL; PYRIDOSTIGMINE; ROCURONIUM; SIMVASTATIN; SUFENTANIL; SUGAMMADEX;

AGED; AIRWAY PRESSURE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CHEMISTRY; CAPNOGRAPHY; CASE REPORT; CONTINUOUS INFUSION; CONVALESCENCE; DISEASE COURSE; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; ELECTROMYOGRAPHY; EXTUBATION; HUMAN; HYPERLIPIDEMIA; MALE; MORNING DOSAGE; MUSCLE FUNCTION; MUSCLE TWITCH; MYASTHENIA GRAVIS; MYOGRAPHY; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR TRANSMISSION; PATIENT MONITORING; PROSTATECTOMY; PTOSIS; PULSE OXIMETRY; SPIROMETRY; THYMECTOMY; TIDAL VOLUME;

AGED; ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; GAMMA-CYCLODEXTRINS; HUMANS; MALE; MYASTHENIA GRAVIS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS; POSTOPERATIVE CARE;

EID: 76649099791     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2009.06236.x     Document Type: Article

References (23)

1. Drachmann DB, De Silva S, Ramsay D, Pestronk A. Humoral pathogenesis of myasthenia gravis. Annals of the New York Academy of Sciences 1987; 505: 90-105.
2. Paton WD, Waud DR. The margin of safety of neuromuscular transmission. The Journal of Physiology 1967; 191: 59-90.
3. Raimond F, Morel E, Bach JF. Evidence for the presence of immunoreactive acetylcholine receptors on human thymus cells. Journal of Neuroimmunology 1984; 6: 31-40.
4. Berrih-Aknin S, Morel E, Raimond F, et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Annals of the New York Academy of Sciences 1987; 505: 50-70.
5. Leventhal SR, Orkin FK, Hirsh RA. Prediction of the need for postoperative mechanical ventilation in myasthenia gravis. Anesthesiology 1980; 53: 26-30.
6. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiologica Scandinavica 2007; 51: 789-808.
7. Gorback MS, Moon RE, Massey JM. Extubation after transsternal thymectomy for myasthenia gravis: a prospective analysis. Southern Medical Journal 1991; 84: 701-6.
8. Viby-Mogensen J, Jensen NH, Engbaek J, Ording H, Skovgaard LT, Chraemmer-Jorgensen B. Tactile and visual evaluation of the response to train-of-four nerve stimulation. Anesthesiology 1985; 63: 440-3.
9. Dupuis JY, Martin R, Tetrault JP. Clinical, electrical and mechanical correlations during recovery from neuromuscular blockade with vecuronium. Canadian Journal of Anaesthesia 1990; 37: 192-6.
10. Nitahara K, Sugi Y, Higa K, Shono S, Hamada T. Neuromuscular effects of sevoflurane in myasthenia gravis patients. British Journal of Anaesthesia 2007; 98: 337-41.
11. Dilger JP, Vidal AM, Mody HI, Liu Y. Evidence for direct actions of general anesthetics on an ion channel protein. A new look at a unified mechanism of action. Anesthesiology 1994; 81: 431-42.
12. Bowman WC. Prejunctional and postjunctional cholinoceptors at the neuromuscular junction. Anesthesia and Analgesia 1980; 59: 935-43.
13. Mann R, Blobner M, Jelen-Esselborn S, Busley R, Werner C. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients. Anesthesiology 2000; 93: 346-50.
14. Nilsson E, Meretoja OA. Vecuronium dose-response and maintenance requirements in patients with myasthenia gravis. Anesthesiology 1990; 73: 28-32.
15. Nilsson E, Muller K. Neuromuscular effects of isoflurane in patients with myasthenia gravis. Acta Anaesthesiologica Scandinavica 1990; 34: 126-31.
16. Eisenkraft JB, Book WJ, Papatestas AE. Sensitivity to vecuronium in myasthenia gravis: a dose-response study. Canadian Journal of Anaesthesia 1990; 37: 301-6.
17. Nilsson E, Paloheimo M, Müller K, Heinonen J. Halothaneinduced variability in the neuromuscular transmission of patients with myasthenia gravis. Acta Anaesthesiologica Scandinavica 1989; 33: 395-401.
18. Macdonald AM, Keen RI, Pugh ND. Myasthenia gravis and atracurium. A case report. British Journal of Anaesthesia 1984; 56: 651-4.
19. Buzello W, Noeldge G, Krieg N, Brobmann GF. Vecuronium for muscle relaxation in patients with myasthenia gravis. Anesthesiology 1986; 64: 507-9.
20. Hunter JM, Bell CF, Florence AM, Jones RS, Utting JE. Vecuronium in the myasthenic patient. Anaesthesia 1985; 40: 848-53.
21. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins III. Toxicological issues and safety evaluation. Journal of Pharmaceutical Sciences 1997; 86: 147-62.
22. Eisenkraft JB, Book WJ, Mann SM, Papatestas AE, Hubbard M. Resistance to succinylcholine in myasthenia gravis: a dose-response study. Anesthesiology 1988; 69: 760-3.
23. Baraka A. Suxamethonium-neostigmine interaction in patients with normal or atypical cholinesterase. British Journal of Anaesthesia 1977; 49: 479-84.